Observers Expect Fewer Large Acquisitions By Indian Drug Makers This Year
This article was originally published in PharmAsia News
Few large acquisitions by Indian drug makers are expected this year as those who took part in expanding the past two years sit back and take stock of their investments, experts say. The new caution is attributed to the failure of recent acquisitions to bring about anticipated results, according to industry observers. In 2006, Indian firms invested $1.2 billion in overseas acquisitions. In 2007, the amount dropped to $500 million. The observers cite pricing pressures in the United States and Europe for the fallback, along with longer waits for the acquisitions to pay off. (Click here for more
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.